HIV-1/2 Rapid
Escherichia Coli.
2 vials of sterile Filtered clear colorless solution.
Protein is >90% pure as determined by 10% PAGE (coomassie staining)
Description
HIV1 gp41 and HIV2 gp160 are used to develop sensitive and specific rapid test. Please note that when ordering for example: 100µg HIV-1/2 Rapid we ship 50µg from each of the antibodies (100µg in total).
Product Specs
This product comprises HIV1 gp41 and HIV2 gp160 antibodies and is intended for use in developing sensitive and specific rapid tests for HIV. It is important to note that when placing an order, for instance, for 100µg of HIV-1/2 Rapid, we will dispatch 50µg of each antibody, totaling 100µg.
The product is supplied as two vials containing a sterile, filtered, clear, and colorless solution.
The formulation for HIV1 gp41 is 25mM PBS, 25mM K2CO3, and 2M Urea.
The formulation for HIV2 gp160 is 25mM PBS, 25mM K2CO3, and 2M Urea.
For short-term storage (up to 1 month), HIV-1/2 Rapid should be kept at 4°C. For longer storage, it is recommended to store it at -20°C. Repeated freezing and thawing should be avoided.
Analysis by 10% PAGE (coomassie staining) indicates that the protein purity is greater than 90%.
Escherichia Coli.
Product Science Overview
The HIV-1/2 Rapid Test Recombinant is a diagnostic tool designed for the rapid detection and differentiation of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) in human serum or plasma. This test is crucial in the early diagnosis and management of HIV infection, which remains a significant global public health challenge.
HIV is a retrovirus that causes HIV infection and leads to acquired immunodeficiency syndrome (AIDS). The virus targets the immune system, specifically the CD4+ T cells, leading to a gradual decline in immune function. This makes the body more susceptible to opportunistic infections and certain cancers. There are two main types of HIV: HIV-1, which is the most prevalent and virulent, and HIV-2, which is less transmissible and largely confined to West Africa.
The development of HIV rapid tests has evolved significantly since the discovery of the virus in the early 1980s. Early tests were based on enzyme-linked immunosorbent assay (ELISA) technology, which required laboratory processing and longer turnaround times. The need for quicker and more accessible testing methods led to the development of rapid tests that could be used at the point of care.
The HIV-1/2 Rapid Test Recombinant is an immunochromatographic assay that utilizes recombinant antigens to detect antibodies specific to HIV-1 and HIV-2. The test involves the following key components and principles:
-
Recombinant Antigens: The test uses highly purified recombinant antigens representing HIV-1 (gp120, gp41, and p24) and HIV-2 (gp36 and gp105). These antigens are immobilized on a nitrocellulose membrane in separate test lines .
-
Sample Application: A sample of human serum or plasma is applied to the test device. As the sample migrates through the membrane, any HIV-specific antibodies present in the sample will bind to the immobilized antigens, forming antibody-antigen complexes .
-
Detection: The bound antibody-antigen complexes are detected by a secondary antibody conjugated to a colorimetric marker, such as colloidal gold or selenium. This results in a visible color change in the test lines, indicating the presence of HIV-specific antibodies .
-
Control Line: The test also includes a control line that changes color to indicate proper sample migration and test validity. This ensures the accuracy and reliability of the test results .
- Speed: Results are typically available within 15-30 minutes, allowing for immediate clinical decision-making.
- Simplicity: The test is easy to perform and does not require specialized laboratory equipment or extensive training.
- Accessibility: It can be used in various settings, including clinics, hospitals, and remote areas, making it an essential tool for widespread HIV screening and diagnosis.
- Differentiation: The ability to differentiate between HIV-1 and HIV-2 infections is crucial for appropriate clinical management and treatment planning.
